China To Receive Discounts On GSK’s New HIV Drug Under Manufacturing Deal
Reuters: Manufacturing deal wins China cheap supply of GSK’s new HIV drug
“China will receive cut-price supplies of GlaxoSmithKline’s new HIV drug Tivicay, following a deal for Shanghai-based Desano Pharmaceuticals to become an additional manufacturer of the medicine’s active ingredient. The collaboration between GSK’s HIV unit ViiV Healthcare and Desano marks an improvement in the business climate for the British drugmaker, which was fined a record three billion yuan ($484 million) in September for bribing Chinese doctors…” (Hirschler, 7/2).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.